Presence of a D8 17 B lymphocyte marker and HLA DR subgroups in patients with rheumatic heart disease

dc.authorid113274en_US
dc.authorid9496en_US
dc.authorid34584en_US
dc.authorid39164en_US
dc.contributor.authorKarakurt, Cemşit
dc.contributor.authorCeliloğlu, Can
dc.contributor.authorÖzgen, Ünsal
dc.contributor.authorYeşilada, Elif
dc.contributor.authorYoloğlu, Saim
dc.contributor.authorZabriskie, John
dc.contributor.authorKoçak, Gülendam
dc.date.accessioned2018-01-25T06:36:56Z
dc.date.available2018-01-25T06:36:56Z
dc.date.issued2011
dc.departmentİnönü Üniversitesien_US
dc.description(Anadolu Kardiyol Derg 2011; 11: 314-8)en_US
dc.description.abstractObjective: The aim of our study was to investigate the association of HLA antigens and a non-HLA protein D8/17 with rheumatic heart disease and its pattern of cardiac involvement. Methods: This cross- sectional observational study included 35 children and 12 adult patients who have rheumatic heart disease and 35 healthy children and 12 healthy adult controls. After physical examination, all patients and control group members were evaluated with 2D and colorcoded echocardiography. B- lymphocyte D8/17 expression was tested by a flow cytometry assay. HLA genotyping was performed using polymerase chain reaction sequence-specific primers. In statistical analysis, Chi-square, unpaired t and Mann-Whitney U tests were used for comparison groups. Results: The percentage of the D8/17-expressing B lymphocytes of the patient group was significantly higher than of the control group (77.3±15.6% vs. 67.7±20.0%, p=0.013). When compared with the control group, the HLA DRB5 (38.6% vs. 13.6%, p=0.007) and HLA DRB1*15 (31.8% vs. 9.0%, p=0.008) expression levels of the patient group were significantly higher and the DRB4 expression of the patient group was significantly lower (29.5% vs. 50.0%, p=0.049). Conclusion: Our findings support the association between HLA Class 2 subgroups and rheumatic heart disease, and an association between D8/17 expression and rheumatic heart disease. Further studies including higher number of patients and control group members should be performed for the confirmation of our results. (Anadolu Kardiyol Derg 2011; 11: 314-8) Key words: Rheumatic heart disease, human leukocyte antigen DR subgroups, beta-lymphocyte D8/17 antigen, flow cytometry.en_US
dc.identifier.citationKarakurt, C., Celiloglu, C., Ozgen, U., Yesilada, E., Yologlu, S., Zabriskie, J., Kocak, G. (2011). Presence of a D8 17 B lymphocyte marker and HLA DR subgroups in patients with rheumatic heart disease. Anadolu Kardiyol Derg 2011; 11: 314-8.en_US
dc.identifier.doi10.5152/akd.2011.082en_US
dc.identifier.endpage318en_US
dc.identifier.issue0en_US
dc.identifier.startpage314en_US
dc.identifier.urihttps://www.journalagent.com/anatoljcardiol/pdfs/AnatolJCardiol_11_4_314_318.pdf
dc.identifier.urihttps://hdl.handle.net/11616/8015
dc.identifier.volume11en_US
dc.language.isoenen_US
dc.publisherAnadolu Kardiyol Derg 2011; 11: 314-8.en_US
dc.relation.ispartofAnadolu Kardiyol Derg 2011; 11: 314-8.en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRheumatic heart diseaseen_US
dc.subjectHuman leukocyte antigen DR subgroupsen_US
dc.subjectBeta-lymphocyte D8/17 antigenen_US
dc.subjectFlow cytometryen_US
dc.titlePresence of a D8 17 B lymphocyte marker and HLA DR subgroups in patients with rheumatic heart diseaseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Makale Dosyası.pdf
Boyut:
75.08 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: